Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Inclusion Criteria:

* Women aged from 18 to 70 years;
* WHO Performance status (ECOG) of 0 or 1
* Core biopsy histologically proven Ⅱa-Ⅲc phase breast cancer (regardless of the type);
* Immunohistochemisty（IHC）：ER-，PR-，CerB2-；Triple negative （ER-PR-Her-2-） Hormone receptor negativity is defined as ER\<10%, PR\<10% (IHC), HER2 negativity is defined as IHC 0-1+, or \[IHC 2+ and FISH or CISH negative\]；
* Adequate hematological function (neutrophil count ³ 2x109/l, platelet count ³ 100x 109/l, Hemoglobin \> 9 g/dl);
* Adequate hepatic function: ASAT and ALAT £ 1.5 ULN alkaline phosphatases £ 2.5 ULN,total bilirubin £ 1,5 ULN;
* Adequate renal function: serum creatinine £ 1.5 ULN;
* Adequate cardiac function, LEVF value \> 50% by Muga scan or echocardiography，and electrocardiogram doe not show specific abnormality；
* Patients accepting contraception intake during the overall length of treatment if of childbearing potential;
* Signed written informed consent.

Exclusion Criteria:

* Any tumor ³ T4a (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast cancer);
* ER+ or PR+ or Her-2 overexpression
* Any chemotherapy, hormonal therapy or radiotherapy before
* Previous cancer in the preceding 10 years;
* Patients already included in another therapeutic trial involving an experimental drug;
* Patients with other concurrent severe and/or uncontrolled medical disease or infection which could compromise participation in the study;
* LEVF \< 50% (MUGA scan or echocardiography);
* Clinically significant cardiovascular disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension (\>150/90), myocardial infarction or cerebral vascular accidents) within 6 months prior to chemotherapy;
* Known prior severe hypersensitivity reactions to agents that will be received;
* Women who are pregnant or breastfeeding. Adequate birth control measures should be taken during study treatment phase;
* Women with a positive pregnancy test en enrollment or prior to study drug administration;
* Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
* Individual deprived of liberty or placed under the authority of a tutor.